Phase 3 study · PureTech · NCT07284602
PureTech's phase 3 deupirfenidone study for idiopathic pulmonary fibrosis
About 1,100 adults are planned, and each person stays in the study for up to about 3 years. By chance, half get deupirfenidone and half get pirfenidone 3 times a day, and neither the participants nor the study team know which.
Get an email when it adds US sites
It is enrolling now. We send an email only when it adds a US site, so you hear if one opens nearer to you. Your email is used for nothing else.
Free email alert
Hear when PureTech's phase 3 deupirfenidone study opens near you
One email when it starts enrolling or lists a new site, with the sites and how to reach the study team. Nothing else.
Opening and new sites for this study only. Stop anytime. We never share your email. Privacy policy
Check the main requirements privately
These questions restate the study's public listing in plain words. Your answers stay on this device and are never sent. You can print a one-page summary to go over with your pulmonologist.
1. Are you 40 or older?
2. Were you first diagnosed with IPF in the last 7 years?
Your pulmonologist's office or your patient portal can tell you the date of your first IPF diagnosis.3. Have you ever taken pirfenidone (Esbriet) or deupirfenidone (LYT-100), even 1 dose?
Esbriet is the brand name of pirfenidone, and your pharmacy record can show any past fills.4. Is your FVC, the breathing test number for how much air you can blow out, at least 45% of predicted?
Your latest breathing test report lists this as FVC % predicted. The study team measures it again at the first study visit.5. Has a high-resolution chest CT scan in the last 12 months shown a definite or probable UIP pattern?
UIP stands for usual interstitial pneumonia, and the radiology report usually says whether it is there. A reader working for the study also checks the scan itself.6. Have you been in the hospital for an IPF flare or another serious breathing problem in the last 3 months?
7. Have you used any tobacco product, or smoked cannabis, in the last 3 months?
The study team also checks for these, which are easier to go over with your pulmonologist:
- Another condition that could explain the lung scarring, or another relevant lung disease
- More emphysema than fibrosis on the latest CT scan, or significant pulmonary hypertension
- A lung transplant, heart disease, chronic liver disease or cancer in the past 5 years
- Prednisone above 10mg a day, or a lower dose that has not been steady for 30 days
- An antifibrotic medicine during the study, though past treatment for up to a year may be allowed
- Trouble swallowing capsules, pregnancy or breastfeeding, or another study drug in the past 90 days
Sites and contact
US sites from the public ClinicalTrials.gov record, refreshed every hour. Only the study team decides who can join.
- Palmtree Clinical Research Inc.Palm Spring, California · Recruiting
- Paradigm Clinical Research Centers LLCRedding, California · Recruiting
- Harmony Medical Research Institute, IncHialeah, Florida · Recruiting
- Clinical Research Specialists, LLCKissimmee, Florida · Recruiting
- Infinity Medical ResearchNorth Dartmouth, Massachusetts · Recruiting
- Renown Regional Medical CenterReno, Nevada · Recruiting
- Pulmonix LLCGreensboro, North Carolina · Recruiting
- Clinical Research Associates of Central PADuBois, Pennsylvania · Recruiting
- Clinical Research of Rock HillRock Hill, South Carolina · Recruiting
- Clinical Trials Center of Middle Tennesee LLCFranklin, Tennessee · Recruiting
- StatCare Pulmonary ConsultantsKnoxville, Tennessee · Recruiting
- Horizon Clinical Research Group.Cypress, Texas · Recruiting
- Premier Pulmonary Critical Care and Sleep MedicineDenison, Texas · Recruiting
- Renovatio ClinicalEl Paso, Texas · Recruiting
- Renovatio ClinicalThe Woodlands, Texas · Recruiting
- Renovatio ClinicalWebster, Texas · Recruiting
Every site's own contact and the full eligibility list are on the official ClinicalTrials.gov listing for NCT07284602.
Questions people ask about PureTech's phase 3 deupirfenidone study
Is PureTech's phase 3 deupirfenidone study enrolling now?
ClinicalTrials.gov lists it as recruiting, as of its last update there on 2026-10-23. Only the study team can confirm whether a particular site is still taking people.
Where are the US sites for PureTech's phase 3 deupirfenidone study?
The listing names 16 US sites, in California, Florida, Massachusetts, Nevada, North Carolina, Pennsylvania and 3 other states. The full list is in the sites section of this page.
Who can join PureTech's phase 3 deupirfenidone study?
About 1,100 adults are planned, and each person stays in the study for up to about 3 years. The main listed requirements are in the pre-check on this page, starting with: adults 40 and older at the time of consent. Only the study team decides who can join.
How do I contact the PureTech's phase 3 deupirfenidone study team?
PureTech gives no central contact on the listing, and each site's own contact is on ClinicalTrials.gov.
Is Trial Friend part of this study?
No. Trial Friend is independent of this study and its sponsor, PureTech. This page restates the public listing in plain words, and nothing here is medical advice; talk with your pulmonologist about whether a study is right for you.
From the public ClinicalTrials.gov record NCT07284602, last updated there 2026-10-23. Questions checked against the listing on November 10, 2026. Trial Friend is independent of this study and its sponsor, and is not a medical provider. Nothing here is medical advice; talk with your pulmonologist about whether a study is right for you.